Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare
Ai in drug discovery, Artificial intelligence, AI, Retrosynthetic analysis, machine learning, Drug Discovery, drug development
SMi Group is delighted to announce the 3rd Annual AI in Drug Discovery conference, taking place on the 14th and 15th March 2022 in London, UK. The 2022 Conference theme is on exploring the opportunities of machine learning.
Chair for the conference is industry expert Darren Green, Director of Molecular Design, GSK.
New to 2022 is the AI in Drug Discovery post conference workshops on: “From Drug Discovery to Healthcare, an AI insight” and “Deciphering AI Based Drug Discovery” taking place on 16th March 2022.
Interested parties can register for the conference and workshops at http://ww.ai-indrugdiscovery.com/PR1 and take advantage of the early bird offer to save £400 which expires 30th November 2021.
The conference will also bring together expert speakers which include:
• Andrew Pattison, Digital Health and Innovation Team, World Health Organisation
• Gregory Vladimer, VP Translation Research, Translation Biology, Exscientia
• Kim Branson, SVP Global Head of Artificial Intelligence and Machine Learning, GSK
• Christian Tyrchan, Associate Director Computational Chemistry, AstraZeneca
• Friedrich Rippmann, Computational Chemistry & Biology, Merck
• Mathew Divine, Senior Data Scientist, Boehringer Ingelheim
• Alexander Hillisch, Pharmaceuticals, R&D, Computational Molecular Design, Bayer AG
• Peter Henstock, Machine Learning & AI Technical Lead, Merck
By attending the conference, attendees will have the chance to:
• Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop
• Engage with regulators about the guidance within machine learning and AI in Drug Discovery
• Learn about the new breakthroughs within clinical trials and the treatment of disease
• Explore the latest technologies in deep learning from leaders within the pharmaceutical industry
• Discuss the impact of big data and how it applies to AI drug discovery within Pharma
Attend the SMi's 3rd annual AI in Drug Discovery conference and explore the latest industry updates in the selection of targets using AI, decision making within drug discovery and closing the loop on AI in drug discovery.
Leading presentations from leaders within the field who will be giving their insights into the latest industry advances and answering the big questions within AI in Drug Discovery.
View the agenda and speaker line–up at http://ww.ai-indrugdiscovery.com/PR1
Sponsored by Optibrium
For sponsorship enquiries contact Alia Malick, Director on +44 (0)20 7827 6168 or e-mail email@example.com
For media enquiries or a press pass contact Simi Sapal, Head of Marketing on +44 (0) 20 7827 6000 or email firstname.lastname@example.org
SMi’s 3rd Annual AI in Drug Discovery 2022
15 – 16 March 2022
--- END ---
45 Curlew Street
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare here
News-ID: 2460884 • Views: 1017
More Releases from SMi Group
Invitation from Conference Chairman, Jeremy Heath, Sutton & East Surrey Water fo …
Building on the success of previous years, SMi’s 11th Annual Smart Water Systems Conference will offer peer-to-peer networking with leaders in the Smart Water Market give delegates in depth knowledge on the requirements you need to build an efficient Advanced Metering Infrastructure. The conference will convene on 4th and 5th April 2022 in London, UK, interested parties can register at http://www.smart-water-systems.com/PR2openPR - register by 31st January 2022 to save £200. The aim
New speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics join 3D …
SMi Group reports: new speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics join the 5th Annual 3D Cell Culture Conference in February 2022 Only four weeks to go until the 5th Annual 3D Cell Culture will now take place as a ‘Virtual Conference’ with online access only on 9th and 10th February 2022. Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to
Registration is now open for Highly Potent Active Pharmaceutical Ingredients 202 …
SMi Group reports: The 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference is set to return in May 2022 with a focus on key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies. SMi Group is delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference, taking place on the 9th and 10th May 2022 in London, UK. The 2022 Conference theme is ensuring product quality
Book to attend the Parallel Trade conference before midnight Friday 28th January …
SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. The 2022 event will be more significant than ever before due to the transition period after Brexit coming to an
More Releases for Drug
Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: firstname.lastname@example.org or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning